

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Withdrawn) A concentrate of a factor VIII:C-containing von Willebrand factor, wherein the concentrate is obtained by fractional precipitation from a liquid comprising factor VIII:C and von Willebrand factor and wherein the concentrate has an increased content of high molecular weight multimers of von Willebrand factor and a ratio of vWF:RCoF activity to vWF:Ag of greater than 1.
2. (Withdrawn) The concentrate as claimed in claim 1 wherein the concentrate is obtained from at least one of human plasma, plasma fractions, and genetically modified cell material.
3. (Withdrawn) The concentrate as claimed in claim 2 wherein the plasma fraction is cryoprecipitate.
4. (Withdrawn) The concentrate as claimed in claim 1 wherein the fractional precipitation is carried out using amino acids and at least one of an alkali metal and an alkaline earth metal salt.
5. (Withdrawn) The concentrate as claimed in claim 4 wherein the amino acid is glycine.
6. (Withdrawn and Previously Amended) The concentrate as claimed in claim 4 wherein the alkali metal salt is NaCl.

7. (Withdrawn) A composition for the treatment of at least one of hemophilia A and von Willebrand syndrome comprising the concentrate of claim 1.

8. (Withdrawn) The composition as claimed in claim 7, further comprising a stabilizer.

9. (Withdrawn) The composition as claimed in claim 8, wherein the stabilizer is calcium ions.

10. (Currently Amended) A process for producing a concentrate of a factor VIII:C-containing von Willebrand factor (vWF/FVIII:C), comprising subjecting a liquid comprising factor VIII:C (FVIII:C) and von Willebrand factor (vWF) to a fractional precipitation using an effective amount of at least one of an alkali metal salt or an alkaline earth metal salt, and an amino acid chosen from glycine, α - or β -alanine, α -, β -, or γ -aminobutyric acid, lysine, valine, asparagine, and glutamic acid, ~~wherein~~ such that the produced concentrate has an increased content of high molecular weight multimers of vWF, and ~~wherein the concentrate has~~ a ratio of von Willebrand factor ristocetin cofactor activity (vWF:RCoF) to von Willebrand factor antigen (vWF:Ag) of greater than 1.

11. (Previously Presented) The process as claimed in claim 10 wherein the amino acid is glycine.

12. (Previously Presented) The process as claimed in claim 10 wherein the alkali metal salt is NaCl.

13. (Currently Amended) The process as claimed in claim 10 wherein the ~~fractional concentration~~ effective amount of the amino acid used in the fractional precipitation is such that the final concentration of amino acid in the precipitation is from about 67 to about 110 ~~70 to 160 g/l~~ and the ~~fractional concentration~~ effective amount of the alkali metal or the alkaline earth metal salt used in the fractional precipitation is such that the final concentration of alkali metal or alkaline earth metal salt in the precipitation is from 100 to 160 g/l.

14. (Canceled)

15. (Previously Presented) The process as claimed in claim 10 further comprising stabilizing the concentrate product produced during said process with at least one of sucrose, glycine, calcium ions, and albumin and pasteurizing said concentrate product produced during said process.

16. (Withdrawn) A process for producing a concentrate of a factor VIII:C- containing von Willebrand factor wherein the concentrate has an increased content of high molecular weight multimers of von Willebrand factor and a ratio of vWF:RCoF activity to vWF:Ag of greater than 1, comprising precipitating of a prothrombin complex by mixing a dissolved cryoprecipitate with an aluminum hydroxide suspension, followed by stirring and removal of the prothrombin complex; precipitating fibrinogen with an amino acid, followed by removal of said fibrinogen; precipitating the vWF:FVIII:C complex using at least one of an alkali metal and an alkaline earth metal salt, followed by dissolving, stabilizing and pasteurizing the resulting precipitate, and subjecting the resulting vWF:FVIII:C complex to fractional precipitation to produce a concentrate.

17. (Withdrawn) The process as claimed in claim 16 wherein the amino acid is glycine.

18. (Withdrawn and Previously Amended) The process as claimed in claim 16 wherein the alkali metal salt is NaCl.

19. (Previously Presented) The process as claimed in claim 10, further comprising prior to the fractional precipitation:

(a) mixing the liquid with an aluminum hydroxide suspension, stirring, and removing the prothrombin complex;

(b) precipitating fibrinogen with an amino acid chosen from glycine, α - or β -alanine, α -, β -, or γ -aminobutyric acid, lysine, valine, asparagine, and glutamic acid and removing said fibrinogen; and

(c) precipitating the vWF/FVIII:C complex using an alkali metal salt or an alkaline earth metal salt.

20. (Previously Presented) The process as claimed in claim 19, wherein the liquid is human plasma, a plasma fraction, or genetically modified cell material.

21. (Previously Presented) The process as claimed in claim 20, wherein the plasma fraction is cryoprecipitate.

22. (Previously Presented) The process as claimed in claim 19, wherein the amino acid is glycine.

23. (Previously Presented) The process as claimed in claim 19, wherein the alkali metal salt is NaCl.

24. (Previously Presented) The process as claimed in claim 15, wherein calcium ions are added to stabilize the concentrate product.